SCHEMBL3314397

SCHEMBL3314397

COc1ccc(C2=NN(C(=O)c3ccccc3Cl)C(c3ccccc3Cl)C2)cc1OC

nearest known ligand 0.62

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.62
KDM4E B2RXH2 2/20 0.62
POLB P06746 1/20 0.62
KMT2A Q03164 4/20 0.60
EGFR P00533 5/20 0.59
HTT P42858 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
MAOA P21397 4/20 0.54
MAOB P27338 4/20 0.54
MEN1 O00255 2/20 0.54
RAB9A P51151 1/20 0.54
PKM P14618 2/20 0.52
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3312868 0.92 KMT2A (0.65) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3319431 0.92 KMT2A (0.61) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3310619 0.91 KDM4E (0.61) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL8206289 0.89 ALDH1A1 (0.57) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3314469 0.87 KMT2A (0.65) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3314426 0.87 KMT2A (0.65) ALDH1A1KDM4EKMT2AEGFRSMN1; SMN2
SCHEMBL3314624 0.87 KMT2A (0.64) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3312492 0.86 KDM4E (0.84) ALDH1A1KDM4EPOLBKMT2AEGFR
SCHEMBL3314410 0.84 PTGS2 (0.62) ALDH1A1KDM4EPOLBKMT2A
SCHEMBL3314554 0.84 XBP1 (0.57) ALDH1A1KDM4EPOLBKMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS KALYPSYS, INC. (US) 2010-04-29 US disclosed
WO-2008045663-A2 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTIINFLAMMATORY AGENTS KALYPSYS, INC. (US) 2008-04-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100105729-A1 ARYL-SUBSTITUTED HETEROCYCLIC PDE4 INHIBITORS AS ANTI-INFLAMMATORY AGENTS PDE4A, PDE4B, PDE4C ALDH1A1 576/4885KDM4E 332/4885POLB 2448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.